Bio-Techne will showcase its solutions at booth #541, featuring our market-leading portfolio of high-grade life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions that are enabling new drug discovery research, accelerating immune cell therapy, and supporting the development of better diagnostic tools. We will also be debuting our Journey into the Tumor Microenvironment video experience in our booth this year. We welcome attendees to explore how different cell types in the tumor microenvironment promote tumor escape through this new interactive platform.
Several scientists from the company will be presenting posters at the conference highlighting our in-house studies in the areas of drug discovery research, automated spatial multiomics, and the development of novel diagnostic tools. These include investigations into validating atypical drug combinations, analyzing the tumor microenvironment by integrated RNA and protein profiling with automated spatial multiomics, developing an exosome/cfDNA methylation blood-based screen for colorectal cancer, and monitoring ESR1 mutations by RT-qPCR in longitudinal studies to predict endocrine therapy resistance.
"We are excited to showcase our portfolio of innovative tools, reagents and workflow solutions that enable the scientific discoveries necessary to advance cancer research," said
Bio-Techne Poster Presentations:
Validation of Atypical Drug Combinations Identified from Combination Databases
Presenter:
Poster Section #39, Poster Board #11, Abstract #943
Unveiling the Spatial Dynamics of the Tumor Microenvironment: Integrated RNA and Protein Profiling on the Same Slide through Automated Spatial Multiomics Analysis
Presenter:
Poster Section #45, Poster Board #20, Abstract #3797
A Kit Targeting Detection of ESR1 Mutations from Circulating Exosomal RNA and Cell-Free DNA Supports Longitudinal Studies into Endocrine Therapy Resistance in a Broadly Accessible RT-qPCR Format
Presenter:
Poster Section #26, Poster Board #2, Abstract #4626
Exosome Based Multiomics Combined with cfDNA Methylation Reveals Complementary Signatures in Blood Based Liquid Biopsy that Carry Promise for Minimally Invasive Colorectal Cancer Screening
Presenter:
Poster Section #51, Poster Board #10, Abstract #LB393
Poster Presentation, In Collaboration
Bladder Cancer Risk Stratification with the Oncuria 10 plex Bead-based Urinalysis Assay Using Three Different Luminex (NASDAQ:LMNX) ® xMAP Instrumentation Platforms
Presenter:
Poster Section #44, Poster Board #29, Abstract #3773
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
david.clair@bio-techne.com
612-656-4416
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.